SMS001 (Paclitaxel) for Non-Small Cell Lung Cancer
This study is looking at a new form of the drug Paclitaxel, called SMS001, for people with non-small cell lung cancer (NSCLC). Doctors want to find a safe dose of SMS001 and see how well it works after lung cancer surgery. You might be able to join if you are 18 to 80 years old, have NSCLC (stages Ib, IIa, IIb, or IIIa N2), and haven't had chemotherapy or radiation for your lung cancer. Your liver and kidney function need to be normal. The main goal is to check for any side effects of SMS001 for up to 52 weeks. They will also look at whether the cancer comes back and how long people live without the disease.
- Study design
- This is an interventional study with a planned enrollment of 42 participants. It is not specified if it's randomized or blinded.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for safety and tolerability for up to 52 weeks. Tumor recurrence will be evaluated at 12-month follow-up.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- Kazuhiro Yasufuku MD, PhD, FRCSC · PRINCIPAL_INVESTIGATOR · University Health Network, Toronto
- Janani S Reisenauer, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Evaluate the incidence of treatment-emergent adverse events (Safety and Tolerability)Day 1 to 52 weeks
Treatment Emergent Adverse Events included laboratory assessments, physical examination findings, and vital signs.